Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)

NCT02454634 is registered in ClinicalTrials.gov with National Center for Tumor Diseases, Heidelberg as lead sponsor.

NCT NCT02454634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02454634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)
Lead sponsor
National Center for Tumor Diseases, Heidelberg
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
September 19, 2017
Enrollment
39 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioma